Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 243-254

  Lorenz, Matthias ^a   Müller, Hans Helge ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY; HEPATOBILIARY DISEASE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; STOMATITIS;

EID: 0343048340     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.243     Document Type: Article

References (59)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Silverberg E, Boring CS, Squires TS: Cancer statistics, 1990. CA Cancer J Clin 40:9-26, 1990
3. Black RJ, Bray F, Ferlay J, et al: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075-1079, 1997
4. Weiss L, Grundmann E, Torhorst J, et al: Haematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150:195-203, 1986
5. Edmondson HA, Peters RL: Neoplasms of the liver, in: Schiff L, Schiff EL (eds). Anonymous Disease of the Liver. Philadelphia, PA, Lippincott, 1987, pp 1103-1158
6. Taylor I, Mullee MA, Campbell MJ: Prognostic index for the development of liver metastases in patients with colorectal cancer. Br J Surg 77:499-501, 1990
7. Kavolius J, Fong Y, Blumgart LH: Surgical resection of metastatic liver tumors. Surg Oncol Clin N Am 5:337-352, 1996
8. Zadavski KE, Lee YTM: Liver metastases from colorectal carcinoma: Incidence, resectability, and survival results. Ann Surg 60:929-932, 1994
9. Scheele J, Stang R, Altendorf-Hofman A, et al: Resection of colorectal liver metastases. World J Surg 19:59-71, 1995
10. Rougier P, Milan C, Lazorthes F, et al: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer: Fondation Francaise de Cancerologie Digestive. Br J Surg 82:1397-1400, 1995
11. Stangl R, Altendorf-Hofmann A, Charnley RM, et al: Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405-1410, 1994
12. Wolmark N, Fisher B, Wieand HS, et al: The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer: Findings from the NSABP clinical trials. Ann Surg 198:743-752, 1983
13. Gilbertsen VA: The results of the surgical treatment of cancer of the rectum. Surg Gynecol Obstet 114:313-318, 1962
14. Sullivan RD, Miller E, Skyes MP: A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1959
15. Ackermann NB, Lien WM, Kondi ES, et al: The blood supply of experimental liver metastases: I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumours. Surgery 66:1067-1072, 1969
16. Ensminger WD, Rosowsky A, Raso V: A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2-oxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978
17. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504, 1984
18. Buchwald H, Grage TB, Vassilipoulos PP, et al: Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45:866-869, 1980
19. Schwartz SI, Jones LS, McLune CS: Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 201:560-567, 1985
20. Daly JM, Kemeny N, Oderman P, et al: Long-term hepatic arterial infusion chemotherapy: Anatomic considerations, operative techniques, and treatment morbidity. Arch Surg 119:936-941, 1984
21. Niederhuber JE, Ensminger W, Gyves J, et al: Regional chemotherapy of colorectal cancer metastases to the liver. Cancer 53:1336-1343, 1984
22. Balch CM, Urist MM, McGregor ML: Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump: A feasibility study in 50 patients. Am J Surg 145:285-290, 1983
23. Ensminger W, Niederhuber J, Gyves J: Effective control of liver metastases from colon cancer with an implanted system for hepatic arterial chemotherapy. Proc Am Soc Clin Oncol 1:94, 1981 (abstr)
24. Kemeny MM, Goldberg DA, Beatty JD, et al: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 57:492-498, 1986
25. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: A randomized trial. Ann Intern Med 107:459-465, 1987
26. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685-693, 1987
27. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group. J Clin Oncol 7:1646-1654, 1989
28. Martin JK, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125:1022-1027, 1990
29. Allen-Mersh T, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255-1260, 1994
30. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 10:1112-1118, 1992
31. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: Is there a survival difference? Meta-analysis of the published literature. Cancer 78:1639-1645, 1996
32. The Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252-258, 1996
33. Hohn DC, Rayner AA, Economou JS, et al: Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 57:465-470, 1986
34. Herrmann G, Lorenz M, Kirkowa-Reimann M, et al: Morphological changes after intra-arterial chemotherapy of the liver. Hepatogastroenterology 34:5-9, 1987
35. Howell JD, McArdle CS, Kerr DJ, et al: A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. Br J Cancer 76:1390-1393, 1997
36. Kerr D, Ledermann JA, McArdle CS, et al: Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 13:2968-2972, 1995
37. Staib-Sebler E, Lorenz M, Gog C, et al: Continuous arterial 5-fluorouracil and folinic acid chemotherapy for colorectal liver metastases. Onkologie 18:240-244, 1995
38. Link KH, Kreuser ED, Safl E, et al: The status of 5-FU and folinic acid (FA, Rescuvolin) in the treatment concept of nonresectable colorectal liver metastases: A comparison of 5-FU/FA i.a. vs. 5-FU/FA i.v. vs. 5-FUDR i.a. vs. 5-FUDR i.a. + i.v. in an observation study. Tumor Diagn Ther 14:224-231, 1993
39. Metzger U, Weder W, Rothlin M, et al: Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. Recent Results Cancer Res 121:198-204, 1991
40. Watkins E Jr, Khazei AM, Nahra KS: Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 130:581-605, 1970
41. Curley SA, Hohn DC, Roh MS: Hepatic artery infusion pumps: Cannulation techniques and other surgical considerations. Langenbecks Arch Chir 375:119-124, 1990
42. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
43. Schoenfeld DA, Richter JR: Nomograms for calculating the number of patients needed for a clinical trial with survival as endpoint. Biometrics 38:163-170, 1982
44. Fleming TR, Harrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 5:348-361, 1984
45. Schulman KA, Yabroff KR: Measuring the cost-effectiveness of cancer care. Oncology (Huntingt) 9:523-533, 1995
46. Schmoll HJ, Büchele T, Schöber C: The role of second-line chemotherapy in colorectal cancer. Onkologie 20:288-294, 1997
47. de Gramont A, Bosset J-F, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
48. Lorenz M, Hottenrott C, Maier P, et al: Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: Influence of modulation with leucovorin. Semin Oncol 19:163-170, 1992 (suppl 3)
49. Hohn DC, Stagg RJ, Friedman MA, et al: The NCOG randomized trial of intravenous vs hepatic arterial FUDR for colorectal cancer metastatic to the liver. Proc Am Soc Clin Oncol 6:85, 1987 (abstr)
50. Burke D, Fordy C, Earlam SA, et al: Hepatic arterial cannulation for regional chemotherapy is safe in patients with a liver metastases volume of less than 1 litre. Br J Cancer 75:1213-1216, 1997
51. O'Connell MJ, Nagorney DM, Bernath AM, et al: Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 16:2528-2533, 1998
52. Mosseri M, Fingert HJ, Varticousky L, et al: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase-C mediated vasoconstriction of vascular smooth muscle. Cancer Res 53:3028-3033, 1993
53. Kemeny MM, Battifora H, Bladney DW, et al: Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 202:176-181, 1985
54. Stagg RJ, Venook AP, Chase JL, et al: Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 83:423-428, 1991
55. Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69:327-334, 1992
56. Wagner JG, Gyves JW, Stetson PL, et al: Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46:1499-1506, 1986
57. Schalhom A, Kühl M: Pharmacology of regional chemotherapy of colorectal liver metastases. Zentralbl Chir 120:764-768, 1995
58. Lorenz M, Staib-Sebler E, Gog C, et al: A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases. Oncology 55:53-58, 1998
59. Campbell KA, Burns RC, Sitzmann JV, et al: Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol 11:822-826, 1993